Ascentage Pharma Group International (HKG:6855)

Market Cap	26.71B
Revenue (ttm)	428.02M
Net Income (ttm)	-1.27B
Shares Out	367.40M
EPS (ttm)	-3.88
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,280,493
Average Volume	3,031,094
Open	72.90
Previous Close	74.50
Day's Range	71.75 - 73.80
52-Week Range	31.35 - 95.35
Beta	0.92
RSI	38.47
Earnings Date	Nov 19, 2025

About HKG:6855

Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company’s primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2009
• Employees: 567
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 6855

Financial Performance

In 2024, HKG:6855's revenue was 980.65 million, an increase of 341.77% compared to the previous year's 221.98 million. Losses were -405.43 million, -56.20% less than in 2023.

Financial numbers in CNY